Eurofins Scientific Shares Bounce Back 2.23% to €61.42, Crossing a Key Threshold
Eurofins Scientific climbs 2.23% to €61.42 in mid-morning trading, within a CAC 40 that is up 0.8%. The bioanalytical testing specialist's stock is among the top gainers in the Paris index, offsetting some of the decline recorded since the April quarterly release.
Stock Crosses Above the MM20 in a Well-Oriented Paris Market
Eurofins Scientific ranks among the top gainers in the CAC 40, up 2.23% at €61.42. The SBF 120 is up 0.81% and the DAX has gained 1.49%, in a supportive European climate.
The stock has crossed above its 20-day moving average, which stands at €60.70, by a margin of 1.2%. However, the MM50 (€62.65) and MM200 (€63.54) remain above the current price, indicating that the medium-term momentum is still weak. Over three months, the decline still reaches 8.71%.
The RSI at 45 indicates a neutral situation, after several sessions in the lower zone. The MACD has slightly crossed above its signal line, but the gap remains narrow. The rebound comes after a challenging period, notably marked by the 10.78% drop on April 22, a penalty for limited organic growth of 2.5% in the first quarter.
Contained Valuation as the Calendar Leads to the General Meeting on May 27
Based on the consensus of eleven analysts (updated May 17), the stock is trading at about 15.3 times the earnings expected for the current fiscal year and 13.1 times those of the next fiscal year. The average in the Health sector is 22.3 times the expected profits. Earnings per share growth is expected at 16.6% year-over-year.
The company also announced a seventh share buyback program covering 4.5% of the capital, launched on April 24. Operationally, the development of hantavirus detection tests, announced on May 14, illustrates the laboratory network's capacity to position itself on emerging epidemics.
The shareholder structure remains marked by a high weight of insiders (36.5% of the capital), with institutional investors representing 32.7%. Next key event: the 2026 general meeting scheduled for May 27, before the publication of the half-yearly results set for September 18.
